#Vienna #Austria #Golden Helix #genomic medicine #Human Genetics

Golden Helix Enhances Genomic Medicine by Partnering with Austrian Human Genetics Labs

Golden Helix, a prominent player in the field of bioinformatics, has recently announced an exciting strategic collaboration with the Austrian public medical genetics laboratories. This partnership is set to significantly boost the genomic capabilities of several laboratories across Austria, a move that is crucial for advancing diagnostics in cancer and hereditary diseases.

The initiative brings together six key Centres for Medical Genetics established in Austria. Their primary goal is to integrate Golden Helix's cutting-edge genomic technologies into seamless clinical workflows. This collaboration, marking over a decade of trust and shared goals, aims to improve patient outcomes substantially by optimizing the application of genomic medicine within the healthcare landscape.

Prof. Dr. med. Zschocke, Chair of the Austrian Society of Human Genetics and Professor at the Medical University of Innsbruck, expressed his enthusiasm regarding the partnership, stating, “This agreement guarantees optimal access to Golden Helix's advanced NGS diagnostic capabilities. We are keen to utilize this for routine diagnostics across all laboratories, which is integral to the Human Genome Project in Austria. Additionally, the capability to operate the software as a medical device in diagnostic mode is crucial for our daily testing operations.” He further mentioned the importance of scaling the software's performance for comprehensive research projects involving human genomes nationwide.

Echoing these sentiments, Dr. Laccone, who heads the Clinical Section at the Institute of Medical Genetics, University of Vienna, shared excitement over how their long-standing relationship with Golden Helix has evolved over the years. As they step into a new era of human diagnostics, the inclusion of long-read sequencing marks an innovative leap forward alongside established short-read technology.

Andreas Scherer, the President and CEO of Golden Helix, conveyed his gratitude for the ongoing collaboration, emphasizing the commitment to delivering advanced clinical diagnostics and personalized healthcare solutions. The partnership signifies a next-level approach, enhancing their efforts in the realm of genomic medicine.

Golden Helix’s software solutions have gained worldwide recognition and are trusted by various institutions, from clinical laboratories to research facilities. This collaboration reinforces the company's position as a leader in enabling precision medicine through effective genomic data analysis and enhanced workflows.

About the Austrian Centres of Medical Genetics

The public medical genetics system in Austria comprises six major institutions affiliated with the Medical Universities of Vienna, Innsbruck, and Graz, plus University Hospitals in Linz and Salzburg and the Center for Medical Genetics at Hanusch Hospital Vienna. These centers work collectively to enhance healthcare quality and precision medicine by collating and organizing data from genetic diagnostics, integrating genome analysis into standard medical care, and contributing to the national healthcare framework.

Their synchronized efforts not only strengthen local collaboration but also contribute to European reference networks for rare diseases and advance the creation of a medically annotated variant database to inform clinical decisions. Together, these centers make up a cohesive network that pushes the boundaries of genomic research, enhances patient outcomes, and supports long-term public health in Austria.

About Golden Helix

With a history of over 25 years, Golden Helix has delivered dependable bioinformatics solutions to hospitals, testing laboratories, research institutions, and national genome programs globally. Their powerful tools for tertiary analysis and genomic warehousing empower clients to identify disease-causing mutations, personalize treatment decisions, and promote precision medicine, especially within rare disease diagnostics, oncology, and pharmacogenetics. This newly announced partnership is yet another step in their unwavering commitment to enhance genomic medicine.